phentermine hydrochloride
STEEL manufacturer BlueScope Steel has flagged the potential sale of its underperforming metallic phentermine hydrochloride business in China and is reviewng the future of its Vietnamese operation. BlueScope managing director Paul O'Malley said today the Suzhou metal phentermine hydrochloride facility in China was performing well but would struggle to break even. Mr O'Malley said the company was committed to China, where it also operates a building division, but the potential sale of the metal phentermine hydrochloride business was on the table. "An exit from China is certainly not contemplated at this stage,'' Mr O'Malley told an investor briefing in Sydney today. "In terms of the metal phentermine hydrochloride line, Suzhou, if we can make that thing pay for itself then it's basically an option. "The margins that we're getting out of that facility at the moment are substantially lower than we expected when we invested in that facility.'' Mr O'Malley said margins were coming under pressure from the high price of raw materials. Elsewhere, BlueScope said it Vietnamese operation, which manufacturers coated and pre painted products for the construction market, would also be reviewed. "Vietnam is operating in the black but it's not at the levels that we expected as well, and we'll have to look at that business as well,'' Mr O'Malley said. Meanwhile, BlueScope said the long term demand outlook for steel is strong, with strength from the Middle East and the Russian economy using more of the building product. "Demand we think will sustain for a long period of time,'' Mr O'Malley said. BlueScope is Australia's largest steel producer with operations across Australia, New Zealand, the United States and Asia. Share this article (What is this?) ... phentermine hydrochloride